Immunicom
Christian Shenouda, M.D. began their work experience as a Clinical Research Physician at the University of Washington from June 2010 to February 2012. Christian then moved on to work as an MD at the National Institutes of Health from February 2012 to May 2016. Following that, they worked as a Medical Doctor at the FDA from May 2016 to October 2021. Currently, they are the Vice President of Regulatory Affairs at Immunicom, Inc. starting from September 2021.
Christian Shenouda, M.D. attended Baylor College of Medicine from 2007 to 2010. No degree or field of study information is provided for this period. There is no information provided regarding education prior to or after attending Baylor College of Medicine. Additionally, it is mentioned that Christian Shenouda also attended University College Dublin, but no information is given about the duration, degree, or field of study at this institution.
This person is not in any offices
Immunicom
Immunicom is developing a non-drug-based cancer therapy with the potential to reduce treatment side effects, enhance therapy response rates and improve cancer patients’ quality of life – all at significantly lower costs and without the side effects and complications prevalent in existing immunotherapy approaches. Immunicom's cancer therapy can allow the body’s natural immune system to directly attack cancer while enhancing the effects of other cancer treatments that may be used concurrently.